Encouraging Phase 3 results for label expansion trial for Xifaxan


Salix Pharmaceuticals (SLXP) reports positive results from a Phase 3 clinical trial evaluating the safety and efficacy of Xifaxan (rifaximin) in patients with irritable bowel syndrome with diarrhea (IBS-D). In the trial, patients received rifaximin 550 mg TID (3x/day) for 14 days. A statistically significant greater proportion of the test group responded to repeat treatment compared to placebo as assessed by the primary endpoint of IBS-related abdominal pain and stool consistency during the four-week treatment-free follow-up period.

The company intends to file an sNDA for the expanded indication of IBS-D. Xifaxin is currently approved as a treatment for the reduction in risk of overt hepatic encephalopathy recurrence in patients at least 18 years of age.

SLXP shares are up 10% premarket on modest volume.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs